With the continuous development of molecular biology technology, nucleic acid drugs have also attracted significant attention due to their tremendous potential in disease diagnosis and treatment. Compared to traditional small molecule drugs and antibody drugs, nucleic acid drugs can fundamentally regulate the expression of pathogenic genes, offering clear advantages such as simple design, short development cycle, strong targeting specificity, a wide range of therapeutic fields, and long-lasting effects. Currently, they are widely used in the treatment of genetic diseases, tumors, viral infections, and other diseases, making them one of the most promising areas in biopharmaceutical research and development today.
2023year2month17On the 1st, co-hosted by Danahelix Life Sciences and organized by Yimao Medical, the event “Focus on Frontiers, Boost Innovation-2023The 'Nucleic Acid Drug Developers Summit ” was held in Shanghai. This forum focused on nucleic acid drug development,CMCThe challenges faced by process quality and the subsequent commercialization are aimed at providing strategies to promote the innovative development of China's nucleic acid drug industry.
Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the event. He delivered a speech on the current situation and future prospects of the nucleic acid drug market and served as the moderator for the guest interviews. He also had discussions with Zhang Peizhuo, Chairman and Chief Scientist of Jimay Gene, Yuan Jijun, Executive Vice President of Aibo Biotech, and Vice President of Darui Biotech.&Co-founders Huang Jinyu and Jian Xin YuanliCDMO companyZhu Min, Senior Vice President of Operations, joined us to discuss the next phase of nucleic acid drug development from research and development to industrialization.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua first briefly introduced the current development status of the nucleic acid drug industry to the attending guests. He pointed out that nucleic acid drugs are targeted at long duration, designed simply, and have a rich array of candidate targets, promising to become the third major type of drug following small molecule and antibody drugs. As of now, there are a total of12model (excluding3Products that have been delisted), already listed2modelmRNADrugs are essentially vaccines. Approved drugs are mostly used for the treatment of rare diseases and the prevention of COVID-19. With the expansion of indications and the continuous development and improvement of technology platforms, the sales of nucleic acid drugs show a growth trend. At the same time, multinational pharmaceutical companies have also been actively deploying nucleic acid drugs in recent years, covering a wide range of disease areas including cardiovascular, hepatitis B, neurological, metabolic, and oncology.
The data shows,2017Year-end2021In [year], the global market scale of nucleic acid drugs has grown from10USD billion growth to620billions, with an average annual compound growth rate exceeding180%. Mao Hua said that with the continuous maturity and commercial success of related key technologies, driven by policy support, multi-party R&D cooperation, and capital investment, the nucleic acid drug market has great potential.
Subsequently, Mao Hua analyzed small nucleic acid drugs andmRNAResearch progress and trend prospects of vaccines and drugs.
According to its introduction, In the field of small nucleic acid drugs, Currently available127The drug is in clinical andNon-Disclosure AgreementStage, mainly comprisingASOandRNAidrugs, and most are stillIperiod andIIPhase clinical stage. In terms of therapeutic areas, the research and development (R&D) projects for small nucleic acid drugs mainly focus on anti-tumor, nervous system, cardiovascular and cerebrovascular fields. There are fewer R&D projects for small nucleic acid drugs targeting the immune system, skin, and hormones, and more than half of the R&D projects for small nucleic acid drugs are orphan drugs. Mao Hua said that in the future, the small nucleic acid drug market will develop towards trends such as technological innovation, expansion of market scale and demand, multi-party collaboration, industrial clusters, and increasingly complete R&D capabilities.
According to a study by Frost & Sullivan, atmRNAVaccines and pharmaceuticals Currently, there are77The drug is in clinical development, mainly comprisingmRNAvaccines, and most are stillIperiod andIIPhase clinical stage. In terms of therapeutic domains,mRNAVaccine and drug research projects are mainly focused on areas such as anti-tumor therapy and treatment of infectious diseases.LNPThe most widely used delivery system.
Mao Hua pointed out that the COVID-19 pandemic has accelerated itmRNAWith the popularization and commercialization of technology, countries have increased their investment inmRNAThe investment in technology has promotedmRNAConstruction and improvement of the technology platform. In the future, as technology applications gradually mature, it is expectedmRNAThe fields of vaccine and drug treatment will continue to expand, with the R&D system gradually becoming complete. The efficacy and safety will also be continuously improved. The industry will achieve synchronous development and win-win cooperation.
Learn more about the nucleic acid drug market
Scan the QR code below to obtain the presentation report.
About Danaher Life Sciences
Danaher is an innovator in the global life science service sector, dedicated to helping customers accelerate research in the field of life sciences with high-quality products and services. It addresses problems and challenges encountered in the analytical domain, promotes the development of medical diagnostics, and enhances laboratory productivity.
The China region of Danaher Life Sciences was established in2019year6month1Today, aiming to take root in the Chinese market and provide better products and services for Chinese users, with the philosophy of 'Focusing on Life, Working Together for a Win', and taking 'Sharing Global Technology to Achieve National Health' as its mission, we strive to create comprehensive integrated solutions for precision medicine and biopharmaceuticals.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences field. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China, and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
